Reengineering Immune System Cells to Treat Glioblastoma

    Emma Shtivelman, PhD

    Glioblastoma multiforme (GBM) is a serious diagnosis. The search for better treatments is ongoing, but with little to show since the U.S. Food and Drug Administration (FDA) approved the use of the chemotherapy drug temozolomide with concurrent radiation 12 years ago, based on data showing modest improvement in patients’ survival. By now, a new cancer treatment approach known as CAR T-cell therapy is famous… Read more »